Latest news
Jazz to buy Actio for up to $1.3B, gaining epilepsy asset - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 19:37:19 GMT$1.32 Billion for a Molecule: Jazz Pharmaceuticals Bets on Rare-Epilepsy Drug With No Approved Rivals - USA HeraldUSA Herald · Mon, 10 Aug 2026 19:01:18 GMTJazz Acquires Actio Bioscience | PharmExec - Pharmaceutical ExecutivePharmaceutical Executive · Mon, 10 Aug 2026 18:37:55 GMTJazz Pharmaceuticals to acquire San Diego biotech for up to $1.3B - The Business JournalsThe Business Journals · Mon, 10 Aug 2026 17:14:00 GMTJazz Pharma Buying Actio In Up To $1.32B Epilepsy Push - Law360Law360 · Mon, 10 Aug 2026 17:05:00 GMTJazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront - TipRanksTipRanks · Mon, 10 Aug 2026 17:00:31 GMTJazz Pharmaceuticals expands rare epilepsy pipeline with Actio Biosciences deal - European Pharmaceutical ReviewEuropean Pharmaceutical Review · Mon, 10 Aug 2026 16:17:36 GMTJazz to buy rare epilepsy drugmaker in potentially $1.3B deal - BioPharma DiveBioPharma Dive · Mon, 10 Aug 2026 16:06:35 GMT